Steatohepatitis/Metabolic Liver Disease News

Each January, Alcohol Change UK runs Dry January, a post-holiday campaign that encourages people to abstain from alcohol for 31 days at the beginning of the year and drink more healthily year-round.

BOSTON — In this video, Rohit Loomba, MD, MHSc, discusses data supporting once-monthly dosing of BOS-580, an investigational, long-acting fibroblast growth factor-21 analog for treatment of metabolic dysfunction-associated steatohepatitis.

A new clinical guideline published in the American Journal of Gastroenterology underscored the need to overcome barriers to alcohol use disorder treatment and expand multidisciplinary care for patients with alcohol-associated liver disease.

In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted how rebranding nonalcoholic fatty liver disease as metabolic dysfunction-associated steatotic liver disease offers a “positive diagnosis” without the associated stigma.

The renaming of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease to metabolic dysfunction-associated steatohepatitis and metabolic dysfunction-associated steatotic liver disease is a long time coming.

In June 2023, 74% of respondents from a multinational, multisociety Delphi process agreed that the term nonalcoholic fatty liver disease was “sufficiently flawed” and 89% preferred nomenclature that described the underlying cause of disease.

Researchers recommended that patients with steatotic liver disease who are at a lower risk for advanced cirrhosis should consume no more than 7.4 grams of alcohol per day, the equivalent of a half a 12 oz. beer or half a glass of wine.

BOSTON — Although primary care physicians play a vital role in managing metabolic dysfunction-associated steatotic liver disease, many are not following guidance on screening, risk stratification or referrals, according to research.

BOSTON — Women who experience food insecurity and have a BMI less than 25 kg/m2 had higher odds of hepatic steatosis compared with overweight women or those with obesity, regardless of HIV status, according to research at The Liver Meeting.

BOSTON — Pegozafermin improved fibrosis and other key noninvasive tests at 24 weeks in patients with metabolic dysfunction-associated steatohepatitis-related cirrhosis, according to data presented at The Liver Meeting.